Intelligence Profile
Clinical Applications
Currently, there are no registered clinical trials for Cartalax in major clinical trial databases, which significantly limits evidence for clinical applications in humans.
The available evidence consists entirely of preclinical laboratory studies conducted between 2011-2020, primarily examining cellular and tissue effects in culture systems. These studies suggest potential applications in several areas:
Anti-Aging and Cellular Regeneration
Laboratory studies indicate Cartalax may influence cellular aging processes across multiple tissue types:
- Mesenchymal stem cells: One 2020 study examined gene expression changes in aging stem cell cultures, suggesting potential modulation of age-related cellular changes
- Skin fibroblasts: A 2016 study investigated peptide regulation of skin cell functions during in vitro aging
- Kidney tissue: Studies from 2014-2015 examined effects on kidney cell cultures from both young and older animals, with one study specifically noting that tripeptides may "slow down aging process in renal cell culture"
Immune System Support
Research has explored effects on immune-related tissues:
- Thymus function: A 2011 study investigated peptidergic regulation of immune cell (thymocyte) processes including differentiation, proliferation, and programmed cell death during thymus aging
Neurological Applications
Limited evidence suggests potential neurological applications:
- Stem cell differentiation: A 2019 study examined effects of short peptides on neuronal differentiation of stem cells
Clinical Evidence Limitations
Important limitation: All available evidence comes from laboratory cell culture and animal tissue studies. There is currently no published clinical trial data demonstrating safety or efficacy in humans for any medical condition.
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Consult healthcare professionals before considering any therapeutic applications.